Company Overview of Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Key Executives for Five Prime Therapeutics, Inc.
Founder, Chief Executive Officer, President and Director
Total Annual Compensation: $525.0K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $382.1K
Chief Business Officer, Executive Vice President and Director
Total Annual Compensation: $364.0K
Compensation as of Fiscal Year 2014.
Five Prime Therapeutics, Inc. Key Developments
Five Prime Therapeutics Announces Key Executive Appointments
Feb 1 16
Five Prime Therapeutics, Inc. announced the appointment of Kevin Baker, Ph.D., as Senior Vice President Development Sciences, to oversee pharmacology, toxicology, bio-analytics, process development, manufacturing and project management. In addition, Robert Sikorski, M.D., Ph.D., was promoted to Senior Vice President of Global Clinical Development where he will oversee all clinical development, pharmacovigilance and pharmacokinetics, and will play a strategic role in advancing Five Prime's immuno-oncology portfolio. Dr. Baker joins Five Prime from Audentes Therapeutics, where he was Senior Vice President, Preclinical Development. Prior to joining Five Prime as Vice President of Global Clinical Development in 2014, Dr. Sikorski was Senior Director, Global Oncology Research and Development at MedImmune (the Biologics Division of AstraZeneca, PLC), where he and his team led the clinical development of a portfolio of immuno-oncology drugs.
Five Prime Therapeutics, Inc. Announces Preliminary Data from the Dose Escalation Portion of the Phase 1 Trial of FPA144 at the ASCO GI Cancers Symposium
Jan 21 16
Five Prime Therapeutics, Inc. announced preliminary data from Part 1 of the ongoing Phase 1 clinical trial of FPA144 in patients with solid tumors, including gastric cancer, at a poster presentation at the American Society of Clinical Oncology’s (ASCO) 2016 Gastrointestinal Cancers Symposium in San Francisco. FPA144 Phase 1 Safety and Pharmacokinetic Summary: Safety data from 27 patients and pharmacokinetic (PK) data from 23 patients from Part 1a (3+3 dose escalation in solid tumor patients) and Part 1b (parallel escalating doses in gastric cancer patients); FPA144 was well tolerated in patients with advanced solid tumors up to 15 mg/kg; No dose-limiting toxicities (DLTs) were observed and a maximum-tolerated dose (MTD) was not reached in Part 1; The most common treatment-emergent adverse events were Grades 1 or 2 and self-limiting; The safety profile appears differentiated from small molecule kinase inhibitors targeting FGF receptors; for example, no treatment-related hyperphosphatemia was observed; The most common treatment-related adverse events were: fatigue (25.9%), nausea (11.1%), diarrhea (7.4%), dizziness (7.4%)and dry eye (7.4%); PK characteristics support once every other week or less frequent dosing. Preliminary Data on Anti-tumor Activity: Anti-tumor activity in patients with gastric cancer whose tumors overexpress the FGFR2b protein (the initial target patient population for FPA144): First radiographic assessment by RECIST 1.1 of anti-tumor activity in six patients with FGFR2b-positive gastric cancer in Part 1b; 2 Partial Responses (1 confirmed who received 6 mg/kg, 1 unconfirmed who received 10 mg/kg); 3 Stable Disease (2 confirmed who received 3 mg/kg and 10 mg/kg, respectively; 1 unconfirmed who received 10 mg/kg); 1 Progressive Disease (who received 10 mg/kg); Patients were classified 3+ by an IHC molecular diagnostic test. Anti-tumor activity in a patient with urothelial bladder cancer: A confirmed Partial Response by CT (RECIST 1.1) and metabolic response by PET was observed in a urothelial bladder cancer patient who received 3 mg/kg from Part 1a; The patient’s tumor was classified 2+ by an IHC molecular diagnostic test, suggesting that FPA144 may be active in tumors with moderate levels of FGFR2b protein overexpression; Encourages investigation of the potential for FPA144 therapy in tumor types other than gastric cancer. All patients who showed anti-tumor activity received doses below the 15 mg/kg dose being assessed in Part 2 of the trial.
Five Prime Therapeutics, Inc. Announces the Resignation of Julie Hambleton as Executive Vice President and Chief Medical Officer and an Employee of the Company, Effective as of February 15, 2016
Jan 19 16
On January 18, 2016, Julie Hambleton notified Five Prime Therapeutics, Inc. that she will resign as Executive Vice President and Chief Medical Officer and an employee of the Company, effective as of February 15, 2016, in order to pursue other interests.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|